CSIMarket Company Name, Ticker, Industry, else..
 
Belite Bio Inc  (BLTE)
 
Price: $169.2100 $-0.23 -0.136%
Day's High: $172.8000030517578 Week Perf: -3.35 %
Day's Low: $ 166.26 30 Day Perf: 3.68 %
Volume (M): 107,337 52 Wk High: $ 200.00
Volume (M$): $ 0 52 Wk Avg: $146.70
Open: $168.50 52 Wk Low: $68.21



 Market Capitalization (Millions $) 5,675
 Shares Outstanding (Millions) 34
 Employees 23
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -78
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Belite Bio, Inc is a Cayman Islands exempted company with limited liability that operates through its subsidiaries. The company develops product candidates, conducts preclinical studies and clinical trials, and seeks regulatory approvals for drugs. Its activities focus on advancing product candidates toward approval, commercialization, and market entry.


   Company Address: 12750 High Bluff Drive Suite 475, San Diego 92130 0
   Company Phone Number: 0   Stock Exchange / Ticker: 0 BLTE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        4.62% 
BMY   -1.26%    
REGN   -4.09%    
TEVA        4.56% 
VRTX   -1.51%    
VTRS        3.15% 
• View Complete Report
   



Clinical Study

Conditional Marketing Authorization Granted for Tinlarebant in Stargardt Disease A New Hope for Patients

Published Mon, Nov 3 2025 10:06 AM UTC

: Belite Bio, Inc. is advancing its investigational therapeutic, Tinlarebant, targeting Stargardt Disease (STGD1), a hereditary retinal dystrophy causing significant vision loss with no currently approved treatments. Recent developments include Conditional Marketing Authorization from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Breakthrough ...
Clinical Study

Promising Advances in Stargardt Disease Treatment A Look at Belite Bios DRAGON Trial Completion,

Published Fri, Sep 12 2025 2:41 PM UTC

In a significant advancement for the field of ophthalmology, Belite Bio Inc., a pioneering clinical-stage drug development company, has announced the completion of its Phase 3 clinical trial, known as DRAGON, which evaluated the efficacy of Tinlarebant in treating Stargardt disease type 1 (STGD1). This announcement, made on September 12, 2025, signifies a crucial milestone i...
Clinical Study

Belite Bio Secures FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease,

Published Wed, May 21 2025 10:32 AM UTC

Belite Bio s Breakthrough in the Treatment of Stargardt DiseaseBelite Bio Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, has recently been thrust into the spotlight with the announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its drug candidate, Tinlarebant, for the treatment of Stargardt Disease (...
Stock Market Announcement

Navigating Challenges: Belite Bios $15 Million Offer Amidst Market Headwinds,

Published Thu, Feb 6 2025 3:35 AM UTC

Belite Bio Secures $15 Million in Direct Offering Amidst Market FluctuationsSAN DIEGO On February 5, 2025, Belite Bio, Inc. (Nasdaq: BLTE), a clinical-stage biopharmaceutical company specializing in developing therapies for degenerative retinal diseases, announced a registered direct offering of approximately $15 million. This strategic move comes as the company seeks to bol...
Product Service News

Advancing Therapeutics in Retinal Disease The Promise of Tinlarebant and the Challenges Facing Belite Bio

Published Tue, Sep 10 2024 12:01 PM UTC

The development of novel therapeutics for retinal diseases represents a significant frontier in pharmaceutical innovation, especially for conditions like Stargardt Disease (STGD1), which currently lacks effective treatment options. Belite Bio, Inc. a clinical-stage biopharmaceutical company based in San Diego, is at the forefront of this endeavor with its recent announcement...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 7.37
PEG (TTM) -

Financial Strength Current
Quick Ratio 36.61
Working Capital Ratio 51.2
Leverage Ratio (MRQ) 0.01
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.31 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 10.52 $
Book Value 22.97 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,374,391
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.